Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade

Key Points

• Immunome shares reached a new 52-week high of $28.04 after Truist raised its price target to $38 from $37 and maintained a “Buy” rating. The stock closed near $27.99, up from the previous close of $26.25.
• Analyst sentiment remains broadly positive, with 12 Buy ratings and one Sell rating; the consensus price target is $34.64. Wedbush and Barclays also maintain bullish outlooks, despite some conflicting bearish ratings.
• Risks include a larger-than-expected quarterly loss of $0.65 per share versus the $0.51 consensus estimate, as well as significant insider selling. Insiders sold 682,310 shares worth about $15.7 million over the past three months, primarily through pre-arranged Rule 10b5-1 plans.

Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) reached a new 52-week high during trading on Thursday after Truist Financial raised their price target on the stock from $37.00 to $38.00. Truist Financial currently has a buy rating on the stock. Immunome traded as high as $28.04 and last traded at $27.99, with a volume of 1561300 shares trading hands. The stock had previously closed at $26.25.

IMNM has been the subject of a number of other research reports. Wedbush increased their target price on shares of Immunome from $31.00 to $35.00 and gave the stock an "outperform" rating in a report on Wednesday. Wall Street Zen downgraded Immunome from a "hold" rating to a "sell" rating in a report on Saturday, May 30th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immunome in a research report on Friday, July 17th. Leerink Partners cut their target price on Immunome from $37.00 to $33.00 and set an "outperform" rating on the stock in a report on Friday, May 15th. Finally, Barclays began coverage on Immunome in a research report on Thursday, May 28th. They issued an "overweight" rating and a $36.00 price target on the stock. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $34.64.

Insider Activity

In other news, insider Robert Lechleider sold 55,000 shares of the company's stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $22.62, for a total value of $1,244,100.00. Following the sale, the insider directly owned 15,805 shares of the company's stock, valued at approximately $357,509.10. This represents a 77.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the sale, the insider owned 50,366 shares of the company's stock, valued at approximately $1,263,682.94. This trade represents a 64.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 682,310 shares of company stock valued at $15,675,566. 7.21% of the stock is currently owned by insiders.

More Immunome News

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a “Buy” rating, implying substantial additional upside from recent levels. The upgraded outlook likely provided the strongest near-term support for Immunome (IMNM). Benzinga analyst price target update
• Positive Sentiment: Immunome reported its second-quarter 2026 results and provided a business update. Investors are likely focused on progress in the company’s clinical-stage antibody programs and its development pipeline, which remain key drivers of the stock’s valuation. Immunome second-quarter 2026 results and business update
• Neutral Sentiment: Director Isaac Barchas sold a combined 98,712 shares from August 10 through August 12 for approximately $2.6 million. The sales reduced his direct ownership to 92,211 shares, but each transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which may make the activity less indicative of a change in his outlook. The transactions were disclosed in SEC filings. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, missing the consensus estimate of a $0.51 loss. The larger-than-expected loss underscores the company’s ongoing cash-burn and execution risks typical of a clinical-stage biotechnology company. Immunome quarterly earnings release

Institutional Investors Weigh In On Immunome

Several institutional investors and hedge funds have recently made changes to their positions in IMNM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Immunome by 44.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company's stock worth $316,000 after purchasing an additional 14,398 shares in the last quarter. Creative Planning acquired a new stake in shares of Immunome during the 2nd quarter worth approximately $167,000. Rhumbline Advisers increased its stake in shares of Immunome by 22.0% in the 2nd quarter. Rhumbline Advisers now owns 108,414 shares of the company's stock valued at $1,008,000 after acquiring an additional 19,526 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Immunome by 3.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company's stock valued at $2,612,000 after acquiring an additional 9,686 shares during the period. Finally, Balyasny Asset Management L.P. bought a new position in Immunome during the second quarter worth $1,021,000. Institutional investors own 44.58% of the company's stock.

Immunome Price Performance

The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of -11.06 and a beta of 2.08. The business's fifty day simple moving average is $21.89 and its 200 day simple moving average is $22.20.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.14). Equities research analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source